IZOZF - Izotropic Accelerates Payor Engagement Activities with Excite International
(TheNewswire)
VANCOUVER, BC - TheNewswire - March 24, 2021 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (C NSX : IZO. CN ) (OTC: IZOZF )(FSE: 1R3 ), a company commercializing true 3D, dedicated breast CTimaging technology for the earlier detection of breast cancers, ispleased to announce it has partnered with EXCITE International(EXCITE), a global network of payors, health systems, patients,scientists, and end-users, to prepare for future commercial adoptionof the IZOview. This will complement the engagement with the U.S.FDA’s Center for Devices & Radiological Health PayorCommunication Task Force. With this EXCITE partnership, Izotropic willengage with EXCITE’s global network to align the device, clinicaltrial design, and regulatory strategy with potential payor groups,methodologists, and expert end-users. The aim is to integrate all ofthe inputs from various groups to increase potential breadth and speedof adoption upon regulatory a pproval. The expectation is forthis work to be completed before the end of the calendar year.
Executive Vice President of Commercial Operations andincoming CEO, Dr. John McGraw, stated, “EXCITE offers real-timeaccess to key opinion leaders, scientists and payor groups in NorthAmerica and Europe. By engaging with internationally recognizedkey-stakeholders early on, just as we did with the FDA Pre-Submission,we’re de-risking our regulatory and commercialization plans andensuring that we’re compliant and can deliver the appropriateclinical evidence needed to support adoption in a given patientpopulation. Simply put, the partnership with EXCITE should increasethe likelihood of rapid adoption of the IZOview Breast CTsystem.”
Founder and CEO of EXCITE, Dr. Leslie Levin, explainedthe network’s process and how it impacts adoption: “EXCITE offers early direct engagement with experts andpayers through early technology review, protocol development, andclinical trial execution. This allows companies to anticipate and meetthe downstream expectations of these important stakeholders. EXCITE isselective in only taking on potentially impactful technologies thatoffer improved patient outcomes and/or health system efficiencies.IZOview clearly offers promise across this spectrum.”
EXCITE recognizes the current process of evidencedevelopment late in the lifecycle is responsible for high payorrejection rates of FDA-approved technologies. The EXCITE processaddresses this issue through early engagement. Dr. Levin stated,“Offering these early insights continues to provide companies withan understanding of expectations of key stakeholders early enough toallow them to develop strategies that meet their expectations and, inso doing, mitigate the risk of downstream rejection. The EXCITEapproach also de-risks investments into technology development.”
Dr. Levin has experience in cancer immunology,biochemistry research, practice experience as an academic medicaloncologist and has participated in numerous cancer-related clinicaltrials, published over 60 original papers, and led the development ofevidence at the policy interface with EXCITE.
More information on Excite International and how theylower investment risk can be found at https://www.exciteinternational.com/site/clinical-trial-development-and-execution
ON BEHALF OF THE BOARD
For investor relations inquiriescontact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routine detection of 3 mm lesionswould result in 1.5 year earlier detection over mammography.
The initial indication for use for breast CT as adiagnostic device has been confirmed. Forthcoming business objectivesinclude identifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional information about Izotropic Corporation canbe found on its website at izocorp.com and by reviewing itsprofile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as suchthey may cause future results of the company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the companynor its shareholders, officers and consultants, shall be liable forany action and the results of any action taken by any person based onthe information contained herein, includingwithout limitation the purchase or sale of company securities. Nothingin this document should be deemed to be medical or other advice of anykind.
Copyright (c) 2021 TheNewswire - All rights reserved.